TY - JOUR
T1 - Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples
AU - Ilié, Marius
AU - Hofman, Véronique
AU - Bontoux, Christophe
AU - Goffinet, Samantha
AU - Benzaquen, Jonathan
AU - Heeke, Simon
AU - Boutros, Jacques
AU - Lassalle, Sandra
AU - Long-Mira, Elodie
AU - Zahaf, Katia
AU - Lalvée, Salomé
AU - Lespinet-Fabre, Virginie
AU - Bordone, Olivier
AU - Tanga, Virginie
AU - Gómez-Caro, Abel
AU - Cohen, Charlotte
AU - Berthet, Jean Philippe
AU - Marquette, Charles Hugo
AU - Hofman, Paul
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/7
Y1 - 2023/7
N2 - Introduction: Both MET expression and the PD-L1 tumor proportion score (TPS) are companion diagnostics for treatment of advanced non-small cell lung carcinoma (aNSCLC) patients. We evaluated the rate of correlation between MET expression and the PD-L1 TPS in matched biopsies and surgically resected specimens from NSCLC patients. Patients and Methods: This retrospective analysis assessed the prevalence and correlation between MET expression (SP44 clone) and the PD-L1 TPS (22C3 clone) by immunohistochemistry together with molecular alterations determined by targeted next-generation sequencing in matched lung biopsy and surgically lung resected specimens from 70 patients with NSCLC. Results: The study found a significant correlation between the MET H-score in surgical samples and matched biopsies (P-value < 0.0001), as well as between the PD-L1 TPS in paired biopsies and surgical samples (P-value < 0.0001). However, there was no significant correlation between the MET H-score or expression subgroups and the PD-L1 TPS in both types of paired samples (P-value = 0.47, and P-value = 0.90). The MET H-score was significantly higher in adenocarcinoma compared to squamous cell carcinoma (P-value < 0.0001). A mutational analysis showed that the MET H-score was significantly higher in NSCLC cases with targetable molecular alterations (P-value = 0.0095), while no significant correlation was found for the PD-L1 TPS. Conclusions: Our study found no significant correlation between PD-L1 and MET expression in samples from NSCLC patients, highlighting the importance of personalized treatment strategies based on individual expression profiles. These findings provide valuable insight into the development of effective immunotherapy and targeted therapy for NSCLC patients.
AB - Introduction: Both MET expression and the PD-L1 tumor proportion score (TPS) are companion diagnostics for treatment of advanced non-small cell lung carcinoma (aNSCLC) patients. We evaluated the rate of correlation between MET expression and the PD-L1 TPS in matched biopsies and surgically resected specimens from NSCLC patients. Patients and Methods: This retrospective analysis assessed the prevalence and correlation between MET expression (SP44 clone) and the PD-L1 TPS (22C3 clone) by immunohistochemistry together with molecular alterations determined by targeted next-generation sequencing in matched lung biopsy and surgically lung resected specimens from 70 patients with NSCLC. Results: The study found a significant correlation between the MET H-score in surgical samples and matched biopsies (P-value < 0.0001), as well as between the PD-L1 TPS in paired biopsies and surgical samples (P-value < 0.0001). However, there was no significant correlation between the MET H-score or expression subgroups and the PD-L1 TPS in both types of paired samples (P-value = 0.47, and P-value = 0.90). The MET H-score was significantly higher in adenocarcinoma compared to squamous cell carcinoma (P-value < 0.0001). A mutational analysis showed that the MET H-score was significantly higher in NSCLC cases with targetable molecular alterations (P-value = 0.0095), while no significant correlation was found for the PD-L1 TPS. Conclusions: Our study found no significant correlation between PD-L1 and MET expression in samples from NSCLC patients, highlighting the importance of personalized treatment strategies based on individual expression profiles. These findings provide valuable insight into the development of effective immunotherapy and targeted therapy for NSCLC patients.
KW - H-score
KW - Immunohistochemistry
KW - MET
KW - NSCLC
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85156253681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85156253681&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2023.107230
DO - 10.1016/j.lungcan.2023.107230
M3 - Article
C2 - 37150140
AN - SCOPUS:85156253681
SN - 0169-5002
VL - 181
JO - Lung Cancer
JF - Lung Cancer
M1 - 107230
ER -